Drug Overview

Simurosertib is a modern, experimental cancer medication designed to target the inner workings of a cell. It is a highly specific “Smart Drug” that aims to stop cancer cells from fixing themselves after they have been damaged. By blocking the cell’s repair kit, this drug makes tumors more likely to stop growing and die.

This medication is currently being studied in clinical trials. It is not available at regular pharmacies and can only be accessed by patients who choose to join approved medical research studies.

• Generic name: Simurosertib (also known as AZD0156)
• US Brand names: None (Investigational drug)
• Drug Class: ATM (Ataxia Telangiectasia Mutated) kinase inhibitor
• Route of Administration: Oral (taken by mouth as a tablet)
• FDA Approval Status: Investigational (Not currently approved by the FDA for standard medical use)

What Is It and How Does It Work? (Mechanism of Action)

Simurosertib is a Targeted Therapy. To understand how it works at the molecular level, we have to look at how cells handle “emergencies.”

Inside every cell is DNA, which acts like an instruction manual. Sometimes, this manual gets “ripped” or broken. This is especially true when a patient receives chemotherapy or radiation. When a “double-strand break” (a serious rip in the DNA) happens, the cell activates a protein called ATM kinase. You can think of ATM as a high-tech alarm system. Once the ATM alarm goes off, it sends signals through pathways like p53 and Chk2 to stop the cell from dividing so it can fix the DNA.

Cancer cells are very good at using this ATM alarm system to survive treatments that are supposed to kill them. Simurosertib works by entering the cancer cell and “cutting the wires” of the ATM alarm system. By inhibiting ATM kinase, the drug prevents the cancer cell from sensing the DNA damage and stops it from starting repairs. Because the cancer cell cannot fix its instruction manual, it becomes too damaged to function and eventually undergoes apoptosis, which is the medical term for programmed cell death.

FDA Approved Clinical Indications

Because simurosertib is still in the research phase, it does not have official FDA-approved uses for the general public. It is being studied in clinical trials for the following:

Oncological uses

• Investigational treatment for advanced solid tumors, such as breast, gastric, and lung cancers.
• Investigational treatment for metastatic prostate cancer.
• Investigational use in combination with other DNA-damaging treatments (like chemotherapy or PARP inhibitors) to make them work better.

Non-oncological

• None at this time.

Dosage and Administration Protocols

In clinical research settings, simurosertib is taken as an oral pill. The exact dose for each patient is determined by the specific rules of the research study.

Dose Adjustments

Because this drug is processed by the liver, doctors monitor liver function blood tests very closely. If liver enzymes rise to concerning levels, the researchers will lower the dose or pause the medication. There are no established dose starting rules for patients with renal (kidney) insufficiency, but kidney health is checked throughout the treatment.

Clinical Efficacy and Research Results

Clinical research data from the 2020 to 2025 period have focused on using simurosertib as a “booster” for other cancer drugs.

Numerical data from early Phase 1 and Phase 2 trials show that simurosertib can be successfully combined with other Targeted Therapies, such as olaparib (a PARP inhibitor). In these studies, researchers found that the combination helped stabilize the disease in patients with advanced cancers who had already failed multiple other treatments. Specifically, the “Clinical Benefit Rate” (meaning the cancer shrank or stayed the same size) was seen in a significant portion of patients with specific genetic markers, such as those with mutations in the BRCA gene. While we are still waiting for long-term survival rates, early results show that blocking the ATM repair system makes tumors much more sensitive to treatment.

Safety Profile and Side Effects

Simurosertib has a safety profile that is common for drugs that interfere with DNA repair.

Black Box Warning

There is no official FDA Black Box Warning for simurosertib because it is an investigational drug.

Common side effects

These occur in more than 10 percent of patients:

• Nausea and vomiting
• Feeling very tired (fatigue)
• Diarrhea
• Decreased appetite
• Low blood cell counts (especially red blood cells and white blood cells)

Serious adverse events

• Severe bone marrow suppression (dangerously low blood counts that increase the risk of infection and bleeding).
• Increased liver enzymes (indicating liver stress).
• Potential for lung inflammation (pneumonitis).

Management strategies

The most common issue is a drop in blood cell counts. To manage this, patients have their blood checked once or twice a week. If the counts drop too low, the doctor will pause the medication to allow the body to create new blood cells. For nausea, standard anti-nausea medications are provided.

Research Areas

Simurosertib is a major focus in Research Areas related to “Synthetic Lethality.” This is a strategy where doctors look for a cancer cell’s “secondary backup plan.” If a cancer cell already has a broken repair tool (like a BRCA mutation), and then simurosertib takes away its ATM repair tool, the cell has zero ways to fix itself and dies. Scientists are also researching whether simurosertib can be used alongside Immunotherapy. The idea is that the extra DNA damage caused by the drug might make the tumor more “visible” to the body’s natural T-cells, helping the immune system join the fight.

Patient Management and Practical Recommendations

Pre-treatment tests to be performed

• Genetic testing of the tumor to check for ATM, BRCA, or other repair gene mutations.
• Complete blood count (CBC) to check baseline blood levels.
• Comprehensive metabolic panel to check liver and kidney function.

Precautions during treatment

Patients must be aware that their immune system may be weaker while taking this drug. It is important to avoid large crowds or people who are sick. Because the drug is a pill, it must be taken consistently every day to keep the ATM repair system turned off.

Do’s and Don’ts list

• Do report any new fever, cough, or unusual bruising to your care team right away.
• Do take your pills at the same time every day to maintain steady drug levels.
• Do keep all follow-up appointments for blood draws.
• Don’t take any new herbal supplements or over-the-counter vitamins without asking your oncologist first.
• Don’t skip doses or change your schedule without talking to your research team.
• Don’t ignore extreme tiredness, as it could be a sign of anemia (low red blood cells).

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. Simurosertib is an investigational medication and is not approved by the Food and Drug Administration (FDA) to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional or your clinical trial oncologist before making any decisions regarding your medical treatment, managing side effects, or participating in a clinical research study.